Poseida Therapeutics, Inc.
PSTX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $278 | $292 | $298 | $303 |
| - Cash | $49 | $31 | $53 | $44 |
| + Debt | $83 | $84 | $85 | $85 |
| Enterprise Value | $311 | $345 | $329 | $344 |
| Revenue | $72 | $26 | $28 | $25 |
| % Growth | 176.2% | -7.7% | 12.6% | – |
| Gross Profit | $72 | $25 | $27 | $21 |
| % Margin | 100% | 94.8% | 95.1% | 83.3% |
| EBITDA | $24 | -$28 | -$21 | -$22 |
| % Margin | 33.3% | -106.9% | -73.3% | -86.6% |
| Net Income | $20 | -$31 | -$24 | -$24 |
| % Margin | 28.2% | -120.8% | -86.3% | -96% |
| EPS Diluted | 0.21 | -0.32 | -0.25 | -0.27 |
| % Growth | 165.6% | -28% | 7.4% | – |
| Operating Cash Flow | -$10 | $38 | -$15 | -$29 |
| Capital Expenditures | -$1 | -$1 | -$0 | -$0 |
| Free Cash Flow | -$10 | $37 | -$15 | -$29 |